Synergy between oral PDE5 inhibitors and topically applied nitric oxide microparticles on the erectile response in a rat model of cavernous nerve injury Article Swipe
Moses T. Tar
,
Andrew Draganski
,
Kelvin P. Davies
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1038/s41443-025-01147-x
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1038/s41443-025-01147-x
This study aimed to evaluate the effectiveness of combining a nitric oxide microparticle delivery system (NO-MP) with various FDA-approved PDE5 inhibitors (PDE5i) for improving erectile responses in a rat model of erectile dysfunction (ED) following cavernous nerve injury, similar to the effects of radical prostatectomy. Male Sprague-Dawley rats, 4–5 months old (weighing ~275 g) underwent bilateral cavernous nerve transection. One week post-surgery animals were administered PDE5i via oral gavage (sildenafil 0.05 mg/kg ( N = 9), tadalafil 0.005 mg/kg ( N = 8), vardenafil 0.01 mg/kg ( N = 7), avanafil 0.1 mg/kg ( N = 8) or untreated ( N = 5) followed by topical application of 250 mg NO-MP to the penile dermis. Erectile responses were assessed by measuring intracorporeal pressure (ICP) and systemic blood pressure (BP) after the application of NO-MP. Compared to NO-MP alone, combination therapy with a PDE5i significantly ( P < 0.05) reduced the time to initial erectile response from 63 ± 21.6 min to 8–23 min (vardenafil: 23 ± 2.3, avanafil: 11 ± 8.1, sildenafil: 19.9 ± 9.8, tadalafil: 18 ± 12.8), and increased the frequency of spontaneous erections from 1 ± 0.71 to 1.7–2.7 per hour (vardenafil: 2.1 ± 0.9, avanafil: 2.7 ± 1.1, sildenafil: 1.7 ± 0.6, tadalafil: 2.5 ± 0.8). No significant changes in maximal ICP/BP, duration of erectile response or baseline ICP/BP were observed. These results suggest that combining NO-MP with PDE5i may provide a promising approach for treating ED after radical prostatectomy.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1038/s41443-025-01147-x
- https://www.nature.com/articles/s41443-025-01147-x.pdf
- OA Status
- hybrid
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4413038575
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4413038575Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1038/s41443-025-01147-xDigital Object Identifier
- Title
-
Synergy between oral PDE5 inhibitors and topically applied nitric oxide microparticles on the erectile response in a rat model of cavernous nerve injuryWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-08-07Full publication date if available
- Authors
-
Moses T. Tar, Andrew Draganski, Kelvin P. DaviesList of authors in order
- Landing page
-
https://doi.org/10.1038/s41443-025-01147-xPublisher landing page
- PDF URL
-
https://www.nature.com/articles/s41443-025-01147-x.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://www.nature.com/articles/s41443-025-01147-x.pdfDirect OA link when available
- Concepts
-
Vardenafil, Erectile dysfunction, Tadalafil, Medicine, Sildenafil, Urology, Nitric oxide, Nerve injury, Premature ejaculation, Penis, Intracavernous injection, Anesthesia, Internal medicine, Surgery, Psychoanalysis, PsychologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4413038575 |
|---|---|
| doi | https://doi.org/10.1038/s41443-025-01147-x |
| ids.doi | https://doi.org/10.1038/s41443-025-01147-x |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40775125 |
| ids.openalex | https://openalex.org/W4413038575 |
| fwci | 0.0 |
| type | article |
| title | Synergy between oral PDE5 inhibitors and topically applied nitric oxide microparticles on the erectile response in a rat model of cavernous nerve injury |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10459 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2738 |
| topics[0].subfield.display_name | Psychiatry and Mental health |
| topics[0].display_name | Sexual function and dysfunction studies |
| topics[1].id | https://openalex.org/T10279 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9993000030517578 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2748 |
| topics[1].subfield.display_name | Urology |
| topics[1].display_name | Urinary Bladder and Prostate Research |
| topics[2].id | https://openalex.org/T10498 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9904000163078308 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2738 |
| topics[2].subfield.display_name | Psychiatry and Mental health |
| topics[2].display_name | Migraine and Headache Studies |
| is_xpac | False |
| apc_list.value | 3190 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4190 |
| apc_paid.value | 3190 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 4190 |
| concepts[0].id | https://openalex.org/C2778822586 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9539861679077148 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q424161 |
| concepts[0].display_name | Vardenafil |
| concepts[1].id | https://openalex.org/C2779929075 |
| concepts[1].level | 2 |
| concepts[1].score | 0.9115571975708008 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q184674 |
| concepts[1].display_name | Erectile dysfunction |
| concepts[2].id | https://openalex.org/C2780816001 |
| concepts[2].level | 3 |
| concepts[2].score | 0.9009543657302856 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q424156 |
| concepts[2].display_name | Tadalafil |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.8727724552154541 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C2776768464 |
| concepts[4].level | 2 |
| concepts[4].score | 0.7928209900856018 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q191521 |
| concepts[4].display_name | Sildenafil |
| concepts[5].id | https://openalex.org/C126894567 |
| concepts[5].level | 1 |
| concepts[5].score | 0.6806089282035828 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q105650 |
| concepts[5].display_name | Urology |
| concepts[6].id | https://openalex.org/C519581460 |
| concepts[6].level | 2 |
| concepts[6].score | 0.48088839650154114 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q207843 |
| concepts[6].display_name | Nitric oxide |
| concepts[7].id | https://openalex.org/C2775991916 |
| concepts[7].level | 2 |
| concepts[7].score | 0.48016873002052307 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2945973 |
| concepts[7].display_name | Nerve injury |
| concepts[8].id | https://openalex.org/C2779892816 |
| concepts[8].level | 2 |
| concepts[8].score | 0.44025421142578125 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q319312 |
| concepts[8].display_name | Premature ejaculation |
| concepts[9].id | https://openalex.org/C2777786686 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4352288544178009 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q58 |
| concepts[9].display_name | Penis |
| concepts[10].id | https://openalex.org/C2781284789 |
| concepts[10].level | 3 |
| concepts[10].score | 0.4348493814468384 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q17004078 |
| concepts[10].display_name | Intracavernous injection |
| concepts[11].id | https://openalex.org/C42219234 |
| concepts[11].level | 1 |
| concepts[11].score | 0.40245819091796875 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q131130 |
| concepts[11].display_name | Anesthesia |
| concepts[12].id | https://openalex.org/C126322002 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3289092779159546 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[12].display_name | Internal medicine |
| concepts[13].id | https://openalex.org/C141071460 |
| concepts[13].level | 1 |
| concepts[13].score | 0.28915542364120483 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[13].display_name | Surgery |
| concepts[14].id | https://openalex.org/C11171543 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q41630 |
| concepts[14].display_name | Psychoanalysis |
| concepts[15].id | https://openalex.org/C15744967 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q9418 |
| concepts[15].display_name | Psychology |
| keywords[0].id | https://openalex.org/keywords/vardenafil |
| keywords[0].score | 0.9539861679077148 |
| keywords[0].display_name | Vardenafil |
| keywords[1].id | https://openalex.org/keywords/erectile-dysfunction |
| keywords[1].score | 0.9115571975708008 |
| keywords[1].display_name | Erectile dysfunction |
| keywords[2].id | https://openalex.org/keywords/tadalafil |
| keywords[2].score | 0.9009543657302856 |
| keywords[2].display_name | Tadalafil |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.8727724552154541 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/sildenafil |
| keywords[4].score | 0.7928209900856018 |
| keywords[4].display_name | Sildenafil |
| keywords[5].id | https://openalex.org/keywords/urology |
| keywords[5].score | 0.6806089282035828 |
| keywords[5].display_name | Urology |
| keywords[6].id | https://openalex.org/keywords/nitric-oxide |
| keywords[6].score | 0.48088839650154114 |
| keywords[6].display_name | Nitric oxide |
| keywords[7].id | https://openalex.org/keywords/nerve-injury |
| keywords[7].score | 0.48016873002052307 |
| keywords[7].display_name | Nerve injury |
| keywords[8].id | https://openalex.org/keywords/premature-ejaculation |
| keywords[8].score | 0.44025421142578125 |
| keywords[8].display_name | Premature ejaculation |
| keywords[9].id | https://openalex.org/keywords/penis |
| keywords[9].score | 0.4352288544178009 |
| keywords[9].display_name | Penis |
| keywords[10].id | https://openalex.org/keywords/intracavernous-injection |
| keywords[10].score | 0.4348493814468384 |
| keywords[10].display_name | Intracavernous injection |
| keywords[11].id | https://openalex.org/keywords/anesthesia |
| keywords[11].score | 0.40245819091796875 |
| keywords[11].display_name | Anesthesia |
| keywords[12].id | https://openalex.org/keywords/internal-medicine |
| keywords[12].score | 0.3289092779159546 |
| keywords[12].display_name | Internal medicine |
| keywords[13].id | https://openalex.org/keywords/surgery |
| keywords[13].score | 0.28915542364120483 |
| keywords[13].display_name | Surgery |
| language | en |
| locations[0].id | doi:10.1038/s41443-025-01147-x |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S53533005 |
| locations[0].source.issn | 0955-9930, 1476-5489 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0955-9930 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | International Journal of Impotence Research |
| locations[0].source.host_organization | https://openalex.org/P4310319965 |
| locations[0].source.host_organization_name | Springer Nature |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319965 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.nature.com/articles/s41443-025-01147-x.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | International Journal of Impotence Research |
| locations[0].landing_page_url | https://doi.org/10.1038/s41443-025-01147-x |
| locations[1].id | pmid:40775125 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | International journal of impotence research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40775125 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5113797586 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Moses T. Tar |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I129975664 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA. |
| authorships[0].institutions[0].id | https://openalex.org/I129975664 |
| authorships[0].institutions[0].ror | https://ror.org/05cf8a891 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I129975664, https://openalex.org/I4210112371 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Albert Einstein College of Medicine |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Moses T. Tar |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA. |
| authorships[1].author.id | https://openalex.org/A5011700253 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Andrew Draganski |
| authorships[1].affiliations[0].raw_affiliation_string | Zylo Therapeutics, Inc, Grenville, SC, USA. |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Andrew Draganski |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Zylo Therapeutics, Inc, Grenville, SC, USA. |
| authorships[2].author.id | https://openalex.org/A5075319685 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-0201-9210 |
| authorships[2].author.display_name | Kelvin P. Davies |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I129975664 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA. [email protected]. |
| authorships[2].institutions[0].id | https://openalex.org/I129975664 |
| authorships[2].institutions[0].ror | https://ror.org/05cf8a891 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I129975664, https://openalex.org/I4210112371 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Albert Einstein College of Medicine |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Kelvin P. Davies |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA. [email protected]. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.nature.com/articles/s41443-025-01147-x.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Synergy between oral PDE5 inhibitors and topically applied nitric oxide microparticles on the erectile response in a rat model of cavernous nerve injury |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10459 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2738 |
| primary_topic.subfield.display_name | Psychiatry and Mental health |
| primary_topic.display_name | Sexual function and dysfunction studies |
| related_works | https://openalex.org/W1973674067, https://openalex.org/W2027435868, https://openalex.org/W2079687248, https://openalex.org/W2116899563, https://openalex.org/W1982339811, https://openalex.org/W150607669, https://openalex.org/W2612747290, https://openalex.org/W2035736227, https://openalex.org/W4230773157, https://openalex.org/W2412895727 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1038/s41443-025-01147-x |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S53533005 |
| best_oa_location.source.issn | 0955-9930, 1476-5489 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0955-9930 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | International Journal of Impotence Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_name | Springer Nature |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319965 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.nature.com/articles/s41443-025-01147-x.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | International Journal of Impotence Research |
| best_oa_location.landing_page_url | https://doi.org/10.1038/s41443-025-01147-x |
| primary_location.id | doi:10.1038/s41443-025-01147-x |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S53533005 |
| primary_location.source.issn | 0955-9930, 1476-5489 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0955-9930 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | International Journal of Impotence Research |
| primary_location.source.host_organization | https://openalex.org/P4310319965 |
| primary_location.source.host_organization_name | Springer Nature |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319965 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.nature.com/articles/s41443-025-01147-x.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | International Journal of Impotence Research |
| primary_location.landing_page_url | https://doi.org/10.1038/s41443-025-01147-x |
| publication_date | 2025-08-07 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W1968400906, https://openalex.org/W2072278433, https://openalex.org/W1990048810, https://openalex.org/W2883055473, https://openalex.org/W1552981071, https://openalex.org/W1966557424, https://openalex.org/W1952446971, https://openalex.org/W2757420307, https://openalex.org/W2038185189, https://openalex.org/W2153486153, https://openalex.org/W2065914485, https://openalex.org/W3160057163, https://openalex.org/W2081228674, https://openalex.org/W1891698889, https://openalex.org/W1996075937, https://openalex.org/W2099719839, https://openalex.org/W2419072075, https://openalex.org/W2800239075, https://openalex.org/W2001471106, https://openalex.org/W2884043993, https://openalex.org/W2109376427, https://openalex.org/W3156108223, https://openalex.org/W2049022539, https://openalex.org/W2162663483 |
| referenced_works_count | 24 |
| abstract_inverted_index.( | 73, 80, 87, 94, 100, 145 |
| abstract_inverted_index.1 | 188 |
| abstract_inverted_index.= | 75, 82, 89, 96, 102 |
| abstract_inverted_index.N | 74, 81, 88, 95, 101 |
| abstract_inverted_index.P | 146 |
| abstract_inverted_index.a | 10, 28, 142, 236 |
| abstract_inverted_index.11 | 169 |
| abstract_inverted_index.18 | 177 |
| abstract_inverted_index.23 | 165 |
| abstract_inverted_index.5) | 103 |
| abstract_inverted_index.63 | 157 |
| abstract_inverted_index.8) | 97 |
| abstract_inverted_index.ED | 241 |
| abstract_inverted_index.No | 211 |
| abstract_inverted_index.by | 105, 120 |
| abstract_inverted_index.g) | 54 |
| abstract_inverted_index.in | 27, 214 |
| abstract_inverted_index.mg | 110 |
| abstract_inverted_index.of | 8, 31, 43, 108, 133, 184, 218 |
| abstract_inverted_index.or | 98, 221 |
| abstract_inverted_index.to | 4, 40, 112, 136, 152, 161, 191 |
| abstract_inverted_index.± | 158, 166, 170, 174, 178, 189, 197, 201, 205, 209 |
| abstract_inverted_index.0.1 | 92 |
| abstract_inverted_index.1.7 | 204 |
| abstract_inverted_index.2.1 | 196 |
| abstract_inverted_index.2.5 | 208 |
| abstract_inverted_index.2.7 | 200 |
| abstract_inverted_index.250 | 109 |
| abstract_inverted_index.7), | 90 |
| abstract_inverted_index.8), | 83 |
| abstract_inverted_index.9), | 76 |
| abstract_inverted_index.One | 60 |
| abstract_inverted_index.and | 125, 180 |
| abstract_inverted_index.for | 23, 239 |
| abstract_inverted_index.may | 234 |
| abstract_inverted_index.min | 160, 163 |
| abstract_inverted_index.old | 51 |
| abstract_inverted_index.per | 193 |
| abstract_inverted_index.rat | 29 |
| abstract_inverted_index.the | 6, 41, 113, 131, 150, 182 |
| abstract_inverted_index.via | 67 |
| abstract_inverted_index.< | 147 |
| abstract_inverted_index.(BP) | 129 |
| abstract_inverted_index.(ED) | 34 |
| abstract_inverted_index.0.01 | 85 |
| abstract_inverted_index.0.05 | 71 |
| abstract_inverted_index.0.6, | 206 |
| abstract_inverted_index.0.71 | 190 |
| abstract_inverted_index.0.9, | 198 |
| abstract_inverted_index.1.1, | 202 |
| abstract_inverted_index.19.9 | 173 |
| abstract_inverted_index.2.3, | 167 |
| abstract_inverted_index.21.6 | 159 |
| abstract_inverted_index.8.1, | 171 |
| abstract_inverted_index.9.8, | 175 |
| abstract_inverted_index.Male | 46 |
| abstract_inverted_index.PDE5 | 20 |
| abstract_inverted_index.This | 1 |
| abstract_inverted_index.from | 156, 187 |
| abstract_inverted_index.hour | 194 |
| abstract_inverted_index.oral | 68 |
| abstract_inverted_index.that | 229 |
| abstract_inverted_index.time | 151 |
| abstract_inverted_index.week | 61 |
| abstract_inverted_index.were | 64, 118, 224 |
| abstract_inverted_index.with | 17, 141, 232 |
| abstract_inverted_index.~275 | 53 |
| abstract_inverted_index.(ICP) | 124 |
| abstract_inverted_index.0.005 | 78 |
| abstract_inverted_index.0.05) | 148 |
| abstract_inverted_index.0.8). | 210 |
| abstract_inverted_index.4–5 | 49 |
| abstract_inverted_index.NO-MP | 111, 137, 231 |
| abstract_inverted_index.PDE5i | 66, 143, 233 |
| abstract_inverted_index.These | 226 |
| abstract_inverted_index.after | 130, 242 |
| abstract_inverted_index.aimed | 3 |
| abstract_inverted_index.blood | 127 |
| abstract_inverted_index.mg/kg | 72, 79, 86, 93 |
| abstract_inverted_index.model | 30 |
| abstract_inverted_index.nerve | 37, 58 |
| abstract_inverted_index.oxide | 12 |
| abstract_inverted_index.rats, | 48 |
| abstract_inverted_index.study | 2 |
| abstract_inverted_index.12.8), | 179 |
| abstract_inverted_index.8–23 | 162 |
| abstract_inverted_index.ICP/BP | 223 |
| abstract_inverted_index.NO-MP. | 134 |
| abstract_inverted_index.alone, | 138 |
| abstract_inverted_index.gavage | 69 |
| abstract_inverted_index.months | 50 |
| abstract_inverted_index.nitric | 11 |
| abstract_inverted_index.penile | 114 |
| abstract_inverted_index.system | 15 |
| abstract_inverted_index.(NO-MP) | 16 |
| abstract_inverted_index.(PDE5i) | 22 |
| abstract_inverted_index.ICP/BP, | 216 |
| abstract_inverted_index.animals | 63 |
| abstract_inverted_index.changes | 213 |
| abstract_inverted_index.dermis. | 115 |
| abstract_inverted_index.effects | 42 |
| abstract_inverted_index.initial | 153 |
| abstract_inverted_index.injury, | 38 |
| abstract_inverted_index.maximal | 215 |
| abstract_inverted_index.provide | 235 |
| abstract_inverted_index.radical | 44, 243 |
| abstract_inverted_index.reduced | 149 |
| abstract_inverted_index.results | 227 |
| abstract_inverted_index.similar | 39 |
| abstract_inverted_index.suggest | 228 |
| abstract_inverted_index.therapy | 140 |
| abstract_inverted_index.topical | 106 |
| abstract_inverted_index.various | 18 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Compared | 135 |
| abstract_inverted_index.Erectile | 116 |
| abstract_inverted_index.approach | 238 |
| abstract_inverted_index.assessed | 119 |
| abstract_inverted_index.avanafil | 91 |
| abstract_inverted_index.baseline | 222 |
| abstract_inverted_index.delivery | 14 |
| abstract_inverted_index.duration | 217 |
| abstract_inverted_index.erectile | 25, 32, 154, 219 |
| abstract_inverted_index.evaluate | 5 |
| abstract_inverted_index.followed | 104 |
| abstract_inverted_index.pressure | 123, 128 |
| abstract_inverted_index.response | 155, 220 |
| abstract_inverted_index.systemic | 126 |
| abstract_inverted_index.treating | 240 |
| abstract_inverted_index.(weighing | 52 |
| abstract_inverted_index.1.7–2.7 | 192 |
| abstract_inverted_index.avanafil: | 168, 199 |
| abstract_inverted_index.bilateral | 56 |
| abstract_inverted_index.cavernous | 36, 57 |
| abstract_inverted_index.combining | 9, 230 |
| abstract_inverted_index.erections | 186 |
| abstract_inverted_index.following | 35 |
| abstract_inverted_index.frequency | 183 |
| abstract_inverted_index.improving | 24 |
| abstract_inverted_index.increased | 181 |
| abstract_inverted_index.measuring | 121 |
| abstract_inverted_index.observed. | 225 |
| abstract_inverted_index.promising | 237 |
| abstract_inverted_index.responses | 26, 117 |
| abstract_inverted_index.tadalafil | 77 |
| abstract_inverted_index.underwent | 55 |
| abstract_inverted_index.untreated | 99 |
| abstract_inverted_index.inhibitors | 21 |
| abstract_inverted_index.tadalafil: | 176, 207 |
| abstract_inverted_index.vardenafil | 84 |
| abstract_inverted_index.(sildenafil | 70 |
| abstract_inverted_index.application | 107, 132 |
| abstract_inverted_index.combination | 139 |
| abstract_inverted_index.dysfunction | 33 |
| abstract_inverted_index.significant | 212 |
| abstract_inverted_index.sildenafil: | 172, 203 |
| abstract_inverted_index.spontaneous | 185 |
| abstract_inverted_index.(vardenafil: | 164, 195 |
| abstract_inverted_index.FDA-approved | 19 |
| abstract_inverted_index.administered | 65 |
| abstract_inverted_index.post-surgery | 62 |
| abstract_inverted_index.transection. | 59 |
| abstract_inverted_index.effectiveness | 7 |
| abstract_inverted_index.microparticle | 13 |
| abstract_inverted_index.significantly | 144 |
| abstract_inverted_index.Sprague-Dawley | 47 |
| abstract_inverted_index.intracorporeal | 122 |
| abstract_inverted_index.prostatectomy. | 45, 244 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7200000286102295 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.42089012 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |